RxDoctor Payments Data

Sai Gundlapalli, MD

Interventional Pain Medicine · Odessa, TXNPI 1447271366

Payments from drug & device makers

$679in general payments, 2019–2025

Across 48 payments — averaging $14.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$344
  • AbbVie$195
  • Vertex$55
  • Redhill Biopharma Inc.$22
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$18
  • Amgen$16
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$66598%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$679 in reported general payments places this provider in the 10th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$442,944
Medicare patients
331
Services billed
8,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen845$21,394
Acetaminophen-CodeineAcetaminophen With Codeine859$15,865
BelbucaBuprenorphine Hcl21$14,392
MounjaroTirzepatide12$12,063
Pregabalin709$11,907
LyricaPregabalin12$10,949
MovantikNaloxegol Oxalate26$10,850
Gabapentin897$10,437
Diclofenac Sodium101$5,690
Tizanidine Hcl469$5,130
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen213$5,031
Duloxetine Hcl423$4,897
Tramadol Hcl452$3,894
Methocarbamol141$3,300
Fentanyl27$3,289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Redhill Biopharma Inc.Movantik$22$10,85026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in Odessa

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →